Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A412177-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $119.90 | |
A412177-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $350.90 | |
A412177-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $503.90 | |
A412177-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $814.90 | |
A412177-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,120.90 |
Synonyms | Asapiprant|932372-01-5|Asapiprant [INN]|BGE-175|BGE175|B2LW71CRGL|S-555739|2-(5-(4-((4-isopropoxyphenyl)sulfonyl)piperazin-1-yl)-2-(oxazol-2-yl)phenoxy)acetic acid|2-(2-(Oxazol-2-yl)-5-(4-(4-((propan-2-yl)oxy)benzenesulfonyl(piperazin-1-yl)phenoxy)acetic |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Asapiprant (S-555739) is a potent and selective antagonist for DP1 receptor with Ki of 0.44 nM. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of DP 1 receptor |
Product Description | Information Asapiprant (S-555739) is a potent and selective antagonist for DP1 receptor with Ki of 0.44 nM. |
ALogP | 3.1 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-[2-(1,3-oxazol-2-yl)-5-[4-(4-propan-2-yloxyphenyl)sulfonylpiperazin-1-yl]phenoxy]acetic acid |
---|---|
INCHI | InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29) |
InChi Key | ZMZNWNTZRWXTJU-UHFFFAOYSA-N |
Canonical SMILES | CC(C)OC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=CC(=C(C=C3)C4=NC=CO4)OCC(=O)O |
Isomeric SMILES | CC(C)OC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=CC(=C(C=C3)C4=NC=CO4)OCC(=O)O |
Alternate CAS | 932372-01-5 |
PubChem CID | 59232326 |
MeSH Entry Terms | 2-(2-(oxazol-2-yl)-5-(4-(4-((propan-2-yl)oxy)benzenesulfonyl(piperazin-1-yl)phenoxy)acetic acid;asapiprant;BGE 175;BGE-175;S-555739 |
Molecular Weight | 501.55 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2426437 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426438 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426439 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426440 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426441 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426442 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426443 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426444 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426445 | Certificate of Analysis | Jan 17, 2024 | A412177 |
B2426446 | Certificate of Analysis | Jan 17, 2024 | A412177 |
1. Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya A, Tomita Y, Kuwajima G, Abraham WM, Deguchi M et al.. (2015) Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma.. Eur J Pharmacol, 765 (3): (15-23). [PMID:26277322] |
2. Wong LR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, Thurman A, Pezzulo AA, Szachowicz PJ, Li P et al.. (2022) Eicosanoid signaling blockade protects middle-aged mice from severe COVID-19.. Nature, 129 (3): (589-97). [PMID:35314834] |